Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II-IV Melanoma Patients and Their Clinicians.

Livingstone A, Morton RL.

Ann Surg Oncol. 2019 Oct 31. doi: 10.1245/s10434-019-08020-4. [Epub ahead of print] No abstract available.

PMID:
31673944
2.

Preferences for Immunotherapy in Melanoma: A Systematic Review.

Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL.

Ann Surg Oncol. 2019 Oct 29. doi: 10.1245/s10434-019-07963-y. [Epub ahead of print] Review.

PMID:
31664622
3.

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.

Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, Long GV, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF.

J Clin Oncol. 2019 Nov 20;37(33):3132-3141. doi: 10.1200/JCO.19.01414. Epub 2019 Sep 25.

PMID:
31553661
4.

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan.

Lo SN, Hong AM, Haydu LE, Ahmed T, Paton EJ, Steel V, Hruby G, Tran A, Morton RL, Nowak AK, Vardy JL, Drummond KJ, Dhillon HM, Mandel C, Scolyer RA, Middleton MR, Burmeister BH, Thompson JF, Fogarty GB.

Trials. 2019 Aug 5;20(1):477. doi: 10.1186/s13063-019-3555-5.

5.

Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma.

Dieng M, Khanna N, Kasparian NA, Costa DSJ, Butow PN, Menzies SW, Mann GJ, Cust AE, Morton RL.

Appl Health Econ Health Policy. 2019 Oct;17(5):669-681. doi: 10.1007/s40258-019-00483-6.

PMID:
31228015
6.

Costs and outcomes of advance care planning and end-of-life care for older adults with end-stage kidney disease: A person-centred decision analysis.

Sellars M, Clayton JM, Detering KM, Tong A, Power D, Morton RL.

PLoS One. 2019 May 31;14(5):e0217787. doi: 10.1371/journal.pone.0217787. eCollection 2019.

7.
8.

Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention?

Morton RL, Asher R, Peyton E, Tran A, Smit AK, Butow PN, Kimlin MG, Dobbinson SJ, Wordsworth S, Keogh L, Cust AE.

Cancer Epidemiol. 2019 Aug;61:8-13. doi: 10.1016/j.canep.2019.05.002. Epub 2019 May 15.

PMID:
31102918
9.

Patients' Views About Skin Self-examination After Treatment for Localized Melanoma.

Dieng M, Smit AK, Hersch J, Morton RL, Cust AE, Irwig L, Low D, Low C, Bell KJL.

JAMA Dermatol. 2019 May 15. doi: 10.1001/jamadermatol.2019.0434. [Epub ahead of print]

PMID:
31090868
10.

Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial.

Dieng M, Morton RL, Costa DSJ, Butow PN, Menzies SW, Lo S, Mann GJ, Cust AE, Kasparian NA.

Br J Dermatol. 2019 Apr 9. doi: 10.1111/bjd.17990. [Epub ahead of print]

PMID:
30965384
11.

Patient-reported advantages and disadvantages of peritoneal dialysis: results from the PDOPPS.

Sukul N, Zhao J, Fuller DS, Karaboyas A, Bieber B, Sloand JA, Subramanian L, Johnson DW, Oliver MJ, Tungsanga K, Tomo T, Morton RL, Morgenstern H, Robinson BM, Perl J; clinical application of PD therapy working group.

BMC Nephrol. 2019 Apr 2;20(1):116. doi: 10.1186/s12882-019-1304-3.

12.

The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study.

Wyld MLR, Morton RL, Clayton P, Wong MG, Jardine M, Polkinghorne K, Chadban S.

Qual Life Res. 2019 Aug;28(8):2081-2090. doi: 10.1007/s11136-019-02173-1. Epub 2019 Apr 1.

PMID:
30937731
13.

False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.

Nijhuis AAG, Dieng M, Khanna N, Lord SJ, Dalton J, Menzies AM, Turner RM, Allen J, Saw RPM, Nieweg OE, Thompson JF, Morton RL.

Ann Surg Oncol. 2019 Jun;26(6):1860-1868. doi: 10.1245/s10434-019-07311-0. Epub 2019 Mar 25.

PMID:
30911946
14.

Use of patient-reported outcome measures and patient-reported experience measures in renal units in Australia and New Zealand: A cross-sectional survey study.

Morton RL, Lioufas N, Dansie K, Palmer SC, Jose MD, Raj R, Salmon A, Sypek M, Tong A, Ludlow M, Boudville N, McDonald S.

Nephrology (Carlton). 2019 Mar 5. doi: 10.1111/nep.13577. [Epub ahead of print]

PMID:
30838732
15.

From Patient-Centered to Person-Centered Care for Kidney Diseases.

Morton RL, Sellars M.

Clin J Am Soc Nephrol. 2019 Apr 5;14(4):623-625. doi: 10.2215/CJN.10380818. Epub 2019 Feb 27. No abstract available.

PMID:
30814112
16.

Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia.

Morton RL, Thompson JF.

BMJ Qual Saf. 2019 Mar;28(3):253-254. doi: 10.1136/bmjqs-2018-009138. Epub 2019 Jan 3. No abstract available.

PMID:
30606805
17.

Effectiveness of Screening and Treatment Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from Endemic Countries in the EU/EEA: A Systematic Review.

Agbata EN, Morton RL, Bisoffi Z, Bottieau E, Greenaway C, Biggs BA, Montero N, Tran A, Rowbotham N, Arevalo-Rodriguez I, Myran DT, Noori T, Alonso-Coello P, Pottie K, Requena-Méndez A.

Int J Environ Res Public Health. 2018 Dec 20;16(1). pii: E11. doi: 10.3390/ijerph16010011.

18.

An International Analysis of Dialysis Services Reimbursement.

van der Tol A, Lameire N, Morton RL, Van Biesen W, Vanholder R.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):84-93. doi: 10.2215/CJN.08150718. Epub 2018 Dec 13.

PMID:
30545819
19.

The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management.

Guitera P, Collgros H, Madronio CM, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, Scolyer RA, Menzies SW, Thompson JF, Cust AE.

Australas J Dermatol. 2019 May;60(2):118-125. doi: 10.1111/ajd.12928. Epub 2018 Oct 9.

PMID:
30302753
20.

The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review.

Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL.

Int J Environ Res Public Health. 2018 Sep 14;15(9). pii: E2013. doi: 10.3390/ijerph15092013.

21.

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J, McGregor I, Olver I, Allsop DJ, Gedye C, Kirby AC, Morton RL, Fox P, Clarke S, Briscoe K, Aghmesheh M, Wong N, Walsh A, Hahn C, Grimison P.

BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.

22.

Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis.

Wong MG, Ninomiya T, Liyanage T, Sukkar L, Hirakawa Y, Wang Y, Wyld MLR, Morton RL, Chadban S, Howard K, Jardine MJ.

Nephrology (Carlton). 2019 Jun;24(6):605-614. doi: 10.1111/nep.13445. Epub 2019 Apr 24.

PMID:
30039893
23.

Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma.

Lim WY, Turner RM, Morton RL, Jenkins MC, Irwig L, Webster AC, Dieng M, Saw RPM, Guitera P, Low D, Low C, Bell KJL.

BMC Health Serv Res. 2018 Jun 20;18(1):477. doi: 10.1186/s12913-018-3291-7.

24.

Impact of CKD on Household Income.

Morton RL, Schlackow I, Gray A, Emberson J, Herrington W, Staplin N, Reith C, Howard K, Landray MJ, Cass A, Baigent C, Mihaylova B; SHARP Collaborative Group.

Kidney Int Rep. 2017 Dec 23;3(3):610-618. doi: 10.1016/j.ekir.2017.12.008. eCollection 2018 May.

25.

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.

Smit AK, Newson AJ, Morton RL, Kimlin M, Keogh L, Law MH, Kirk J, Dobbinson S, Kanetsky PA, Fenton G, Allen M, Butow P, Dunlop K, Trevena L, Lo S, Savard J, Dawkins H, Wordsworth S, Jenkins M, Mann GJ, Cust AE.

Contemp Clin Trials. 2018 Jul;70:106-116. doi: 10.1016/j.cct.2018.05.014. Epub 2018 May 23.

PMID:
29802966
26.

The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.

Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, van der Werf MJ, Noori T, Pottie K, Matteelli A, Zenner D, Morton RL.

Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00543.

27.

The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review.

Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, Noori T, van der Werf MJ, Pottie K, Matteelli A, Zenner D, Morton RL.

Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00542.

28.

Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma.

Lim WY, Morton RL, Turner RM, Jenkins MC, Guitera P, Irwig L, Webster AC, Dieng M, Saw RPM, Low D, Low C, Bell KJL.

JAMA Dermatol. 2018 Apr 1;154(4):420-427. doi: 10.1001/jamadermatol.2018.0021.

29.

Case-control study of end-of-life treatment preferences and costs following advance care planning for adults with end-stage kidney disease.

Sellars M, Morton RL, Clayton JM, Tong A, Mawren D, Silvester W, Power D, Ma R, Detering KM.

Nephrology (Carlton). 2019 Feb;24(2):148-154. doi: 10.1111/nep.13230.

PMID:
29389053
30.

A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia.

Watts CG, Wortley S, Norris S, Menzies SW, Guitera P, Askie L, Mann GJ, Morton RL, Cust AE.

Appl Health Econ Health Policy. 2018 Apr;16(2):235-242. doi: 10.1007/s40258-017-0368-0.

PMID:
29305821
31.

Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia.

Read RL, Madronio CM, Cust AE, Goumas C, Watts CG, Menzies S, Curtin AM, Mann G, Thompson JF, Morton RL.

Ann Surg Oncol. 2018 Mar;25(3):617-625. doi: 10.1245/s10434-017-6319-z. Epub 2018 Jan 3.

PMID:
29299710
32.

Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma.

Dieng M, Kasparian NA, Cust AE, Costa DSJ, Tran A, Butow PN, Menzies SW, Mann GJ, Morton RL.

JAMA Dermatol. 2018 Jan 1;154(1):52-59. doi: 10.1001/jamadermatol.2017.4701.

33.

An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD.

Sellars M, Clayton JM, Morton RL, Luckett T, Silvester W, Spencer L, Pollock CA, Walker RG, Kerr PG, Tong A.

Am J Kidney Dis. 2018 Feb;71(2):216-224. doi: 10.1053/j.ajkd.2017.07.021. Epub 2017 Nov 11.

PMID:
29132946
34.

Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.

Critselis E, Vlahou A, Stel VS, Morton RL.

Nephrol Dial Transplant. 2018 Mar 1;33(3):441-449. doi: 10.1093/ndt/gfx068.

PMID:
29106632
35.

A systematic review and meta-analysis of utility estimates in melanoma.

Tran AD, Fogarty G, Nowak AK, Espinoza D, Rowbotham N, Stockler MR, Morton RL.

Br J Dermatol. 2018 Feb;178(2):384-393. doi: 10.1111/bjd.16098. Epub 2018 Jan 17.

PMID:
29077983
36.

A Discrete Choice Study of Patient Preferences for Dialysis Modalities.

Walker RC, Morton RL, Palmer SC, Marshall MR, Tong A, Howard K.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):100-108. doi: 10.2215/CJN.06830617. Epub 2017 Oct 19.

37.

Further approaches to reduce the cost of renal replacement therapy.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Van Biesen W, Zoccali C; European Kidney Health Alliance.

Nat Rev Nephrol. 2017 Nov;13(11):720. doi: 10.1038/nrneph.2017.136. Epub 2017 Sep 25. No abstract available.

PMID:
28944776
38.

Prevention and assessment of infectious diseases among children and adult migrants arriving to the European Union/European Economic Association: a protocol for a suite of systematic reviews for public health and health systems.

Pottie K, Mayhew AD, Morton RL, Greenaway C, Akl EA, Rahman P, Zenner D, Pareek M, Tugwell P, Welch V, Meerpohl J, Alonso-Coello P, Hui C, Biggs BA, Requena-Méndez A, Agbata E, Noori T, Schünemann HJ.

BMJ Open. 2017 Sep 11;7(9):e014608. doi: 10.1136/bmjopen-2016-014608.

39.

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.

Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, Simes J, Stockler M, Morton RL.

Pharmacoeconomics. 2018 Jan;36(1):67-78. doi: 10.1007/s40273-017-0565-6.

PMID:
28866778
40.

A review of international clinical practice guidelines for the use of oxygen in the delivery room resuscitation of preterm infants.

Wilson A, Vento M, Shah PS, Saugstad O, Finer N, Rich W, Morton RL, Rabi Y, Tarnow-Mordi W, Suzuki K, Wright IM, Oei JL.

Acta Paediatr. 2018 Jan;107(1):20-27. doi: 10.1111/apa.14012. Epub 2017 Sep 6. Review.

PMID:
28792628
41.

Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?

Smit AK, Keogh LA, Newson AJ, Butow PN, Dunlop K, Morton RL, Kirk J, Espinoza D, Cust AE.

Br J Dermatol. 2017 Sep;177(3):779-790. doi: 10.1111/bjd.15744. Epub 2017 Jul 20.

PMID:
28627002
42.

Reducing the costs of chronic kidney disease while delivering quality health care: a call to action.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Biesen WV, Zoccali C; European Kidney Health Alliance.

Nat Rev Nephrol. 2017 Jul;13(7):393-409. doi: 10.1038/nrneph.2017.63. Epub 2017 May 30. Review.

PMID:
28555652
43.

GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence.

Welch VA, Akl EA, Pottie K, Ansari MT, Briel M, Christensen R, Dans A, Dans L, Eslava-Schmalbach J, Guyatt G, Hultcrantz M, Jull J, Katikireddi SV, Lang E, Matovinovic E, Meerpohl JJ, Morton RL, Mosdol A, Murad MH, Petkovic J, Schünemann H, Sharaf R, Shea B, Singh JA, Solà I, Stanev R, Stein A, Thabaneii L, Tonia T, Tristan M, Vitols S, Watine J, Tugwell P.

J Clin Epidemiol. 2017 Oct;90:76-83. doi: 10.1016/j.jclinepi.2017.01.015. Epub 2017 Apr 4.

44.

Optimising care for children with kidney disease.

Caskey FJ, Morton RL.

Lancet. 2017 May 27;389(10084):2084-2086. doi: 10.1016/S0140-6736(17)30267-2. Epub 2017 Mar 20. No abstract available.

PMID:
28336051
45.

Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications.

Morton RL, Tran A, Vessey JY, Rowbotham N, Winstanley J, Shannon K, Spillane AJ, Stretch J, Thompson JF, Saw RP.

Ann Surg Oncol. 2017 Aug;24(8):2071-2079. doi: 10.1245/s10434-017-5842-2. Epub 2017 Mar 20.

PMID:
28321690
46.

Home hemodialysis: a comprehensive review of patient-centered and economic considerations.

Walker RC, Howard K, Morton RL.

Clinicoecon Outcomes Res. 2017 Feb 16;9:149-161. doi: 10.2147/CEOR.S69340. eCollection 2017. Review.

47.

Clinicians' Perspectives on Advance Care Planning for Patients With CKD in Australia: An Interview Study.

Sellars M, Tong A, Luckett T, Morton RL, Pollock CA, Spencer L, Silvester W, Clayton JM.

Am J Kidney Dis. 2017 Sep;70(3):315-323. doi: 10.1053/j.ajkd.2016.11.023. Epub 2017 Feb 17.

PMID:
28216281
48.

Measuring trade-offs in nephrology: a systematic review of discrete choice experiments and conjoint analysis studies.

Clark MD, Szczepura A, Gumber A, Howard K, Moro D, Morton RL.

Nephrol Dial Transplant. 2018 Feb 1;33(2):348-355. doi: 10.1093/ndt/gfw436.

PMID:
28158746
49.

Māori patients' experiences and perspectives of chronic kidney disease: a New Zealand qualitative interview study.

Walker RC, Walker S, Morton RL, Tong A, Howard K, Palmer SC.

BMJ Open. 2017 Jan 19;7(1):e013829. doi: 10.1136/bmjopen-2016-013829.

50.

Fear of new or recurrent melanoma after treatment for localised melanoma.

Bell KJL, Mehta Y, Turner RM, Morton RL, Dieng M, Saw R, Guitera P, McCaffery K, Low D, Low C, Jenkins M, Irwig L, Webster AC.

Psychooncology. 2017 Nov;26(11):1784-1791. doi: 10.1002/pon.4366. Epub 2017 Feb 2.

PMID:
28052599

Supplemental Content

Loading ...
Support Center